The Nasdaq Composite slid more than 3% in Monday’s trading as a slate of AI-related plays, including chip darling Nvidia, ...

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average ( ^DJI 0.78%) had just a ...

Oil futures resume their rally with winter demand and prospects of supply curbs due to U.S. sanctions pushing prices to their highest level since August. "U.S. sanctions against Russia remain the ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly said it received Food and Drug Administration approval ...

After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst. Warren Buffett Sold Over $134 Billion Worth of Stock in 2024, But His Most Recent $200 Million in ...

Inflation data this week has come in below forecasts. Earnings season is off to a solid start. Is this the medicine the ...

U.S. stocks are rallying after financial markets worldwide got a shot of adrenaline from an encouraging update on U.S.

U.S. stock futures point higher ahead of closely watched CPI report, JPMorgan Chase stock rises on better-than-expected results, and economists expect annual inflation to have risen in December.

Despite today's revenue miss, Bernstein stands firm on their long-term outlook for Eli Lilly. This optimism is reflected in the broader analyst consensus, with an average rating of 1.75 (Strong ...